Susquehanna International Group’s Neuphoria Therapeutics NEUP Stock Holding History

Susquehanna International Group’s Portfolio NEUP Stock Details NEUP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,845	Closed	-$14.9K	–	13470
2024 Q3	$14.9K	Buy	+2,845	New	+$22.5K	﹤0.01%	11675

Other funds holding NEUP

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group's NEUP Position: Q4 2024 in Review

Susquehanna International Group sold out of Neuphoria Therapeutics (NEUP) in Q4 2024, closing a stake of 2,845 shares — an estimated $14.9K sold.

Susquehanna International Group first reported a position in NEUP in Q3 2024 and held it in 1 quarter. The position peaked at $14.9K in Q3 2024. 8 funds tracked by Wall St. Rank hold NEUP as of Q4 2024.

Susquehanna International Group reported no remaining Neuphoria Therapeutics position as of Q4 2024 after selling out during the quarter.
Susquehanna International Group sold 2,845 Neuphoria Therapeutics shares in Q4 2024, an estimated $14.9K.
Susquehanna International Group first reported a position in Neuphoria Therapeutics in Q3 2024 and held it in 1 quarter.
Susquehanna International Group's Neuphoria Therapeutics position peaked at $14.9K in Q3 2024.
8 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q4 2024.

Based on Susquehanna International Group's 13F filing for Q4 2024, filed 14 Feb 2025.